Category: Janetka Publications

Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.

Owusu B.Y., Thomas S., Venukadasula P., Han Z., Janetka J.W., Galemmo R.A. Jr., & Klampfer L. (2017). “Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.” Oncotarget. 2017 May 29;8(38):63014-63025. doi: 10.18632/oncotarget.18260. eCollection 2017 Sep 8. (Abstract)

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease.

Mydock-McGrane L.K., Hannan T.J., & Janetka J.W. (2017). “Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease.” Expert Opin Drug Discov. 2017 Jul;12(7):711-731. doi: 10.1080/17460441.2017.1331216. Epub 2017 Jun 2. (Abstract)

Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1.

Budelier M.M., Cheng W.W.L., Bergdoll L., Chen Z.W., Janetka J.W., Abramson J., Krishnan K., Mydock-McGrane L., Covey D.F., Whitelegge J.P., & Evers A.S. (2017). “Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1.” J Biol Chem. 2017 Jun 2;292(22):9294-9304. doi: 10.1074/jbc.M116.773069. Epub 2017 Apr 10. (Abstract)

Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins.

Budelier M.M., Cheng W.W., Bergdoll L., Chen Z.W., Abramson J., Krishnan K., Qian M., Covey D.F., Janetka J.W., & Evers A.S. (2017). “Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins.” Anal Chem. 2017 Feb 21;89(4):2636-2644. doi: 10.1021/acs.analchem.6b05003. Epub 2017 Feb 9. (Abstract)

Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions.

Kalas V., Pinkner J.S., Hannan T.J., Hibbing M.E., Dodson K.W., Holehouse A.S., Zhang H., Tolia N.H., Gross M.L., Pappu R.V., Janetka J., & Hultgren S.J. (2017). “Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions.” Sci Adv. 2017 Feb 10;3(2):e1601944. doi: 10.1126/sciadv.1601944. eCollection 2017 Feb. (Abstract)

Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections.

Mydock-McGrane L., Cusumano Z., Han Z., Binkley J., Kostakioti M., Hannan T., Pinkner J.S., Klein R.D., Kalas V., Crowley J., Rath N.P., Hultgren S.J., & Janetka J.W. (2016). “Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections.” J Med Chem. 2016 Oct 27;59(20):9390-9408. Epub 2016 Oct 14. (Abstract)

C‐Glycosides, Array‐based Addressable Libraries, and the Versatility of Constant Current Electrochemistry

Smith J.A., Xu G., Feng R., Janetka J.W., & Moeller, K.D. (2016). “C‐Glycosides, Array‐based Addressable Libraries, and the Versatility of Constant Current Electrochemistry” Electroanalysis. 2016, Volume 28, Issue 11, Pages: 2808-2817. DOI: 10.1002/elan.201600200 (Abstract)

Characterization of parasite-specific indels and their proposed relevance for selective anthelminthic drug targeting.

Wang Q., Heizer E., Rosa B.A., Wildman S.A., Janetka J.W., & Mitreva, M. (2016). “Characterization of parasite-specific indels and their proposed relevance for selective anthelminthic drug targeting.” Infect Genet Evol. 2016 Apr;39:201-211. doi: 10.1016/j.meegid.2016.01.025. Epub 2016 Jan 30. (Abstract)

α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.

Han Z., Harris P.K.W., Karmakar P., Kim T., Owusu B.Y., Wildman S.A., Klampfer, L., & Janetka J.W. (2016). “α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.” ChemMedChem. 2016 Mar 17;11(6):585-99. doi: 10.1002/cmdc.201500600. Epub 2016 Feb 17. (Abstract)